feedburner

Enter your email address:

Delivered by FeedBurner

GSK, Vir Biotech to expand COVID-19 research partnership for other diseases

As a part of the deal to research and develop monoclonal antibody
treatments for influenza and other respiratory illnesses, GSK will
make a further $120 million equity investment in Vir and an additional
upfront payment of $225 million.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases/articleshow/81062795.cms



0 comments:

Post a Comment